Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | HTR1D | P28221 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29379037 | 1.00 | KDM4E (1.00) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL29287896 | 0.83 | KDM4E (0.71) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL1719866 | 0.83 | HTR2C (0.70) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL7392593 | 0.82 | JAK2 (0.69) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL3417195 | 0.81 | HTR2C (0.67) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL7538898 | 0.79 | HTR2C (0.66) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL5845143 | 0.79 | HTR2C (0.65) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL7867965 | 0.79 | HTR2C (0.65) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL2462725 | 0.79 | KDM4E (0.65) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 | |
| SCHEMBL6599102 | 0.79 | HTR2C (0.65) | KDM4EHTR2CHSD17B10ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0058975-B1 | SUBSTITUTED N-(4-INDOLYL-PIPERIDINO-ALKYL) BENZIMIDAZOLONES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1984-12-12 | — | — | EP | claimed |
| EP-0058975-A1 | Substituted N-(4-indolyl-piperidino-alkyl) benzimidazolones, processes for their preparation and their use as pharmaceutical preparations | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1982-09-01 | — | — | EP | claimed |
| US-4196209-A | Treating psychic disorders with piperidyl-indoles | ROUSSEL UCLAF (FR) | 1980-04-01 | — | — | US | claimed |
| US-20250034106-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2025-01-30 | — | — | US | disclosed |
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20240091202-A1 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | UNIVERSITÄT BASEL (CH) | 2024-03-21 | — | — | US | disclosed |
| EP-4301358-A2 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | Universität Basel Vizerektorat Forschung (CH) | 2024-01-10 | — | — | EP | disclosed |
| CN-117295521-A | Compositions for treating EBV-associated diseases or conditions | 巴塞尔大学 | 2023-12-26 | — | — | CN | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019366-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019368-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | MINDSET PHARMA INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| US-4548939-A | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones | JANSSEN PHARMACEUTICA N. V. (BE) | 1985-10-22 | — | — | US | disclosed |
| EP-0058975-B1 | SUBSTITUTED N-(4-INDOLYL-PIPERIDINO-ALKYL) BENZIMIDAZOLONES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PREPARATIONS | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1984-12-12 | — | — | EP | disclosed |
| US-4359468-A | ALSO USEFUL AS HYPOTENSIVE AGE NTS | BOEHRINGER INGELHEIM LTD. (US) | 1982-11-16 | — | — | US | disclosed |
| EP-0058975-A1 | Substituted N-(4-indolyl-piperidino-alkyl) benzimidazolones, processes for their preparation and their use as pharmaceutical preparations | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4324790-A | NEUROLEPTIC, ANTIEMETIC | ROUSSEL UCLAF (FR) | 1982-04-13 | — | — | US | disclosed |
| US-4278677-A | Tetrahydropyridinyl indoles | ROUSSEL UCLAF (FR) | 1981-07-14 | — | — | US | disclosed |
| EP-0022705-A1 | Derivatives of tetrahydropyridinyl-indol and their salts, their preparation, their application as medicines, and compositions containing them | ROUSSEL-UCLAF (FR) | 1981-01-21 | — | — | EP | disclosed |
| US-4196209-A | Treating psychic disorders with piperidyl-indoles | ROUSSEL UCLAF (FR) | 1980-04-01 | — | — | US | disclosed |
| US-4100291-A | HYPOTENSIVE | ROUSSEL UCLAF (FR) | 1978-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376052-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR5A, TPH2 | KDM4E 3293/4885HTR2C 8/4885HSD17B10 2209/4885 |
| US-20250034106-A1 | 3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | TPH1, HTR3A, HTR1A | KDM4E 3948/4885HTR2C 7/4885HSD17B10 2262/4885 |
| US-20240091202-A1 | COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS | IDO1, IDO2, MALT1 | KDM4E 611/4885HTR2C 4415/4885HSD17B10 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.